The nominal deal value is $11.5B, including assumption of debt.
TMO seems willing to acquire almost any company in the life-sciences industry. It may be a bit too much like Valeant and Tyco for my taste. (No position.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.